-
1.发明申请公开(公告)号：US20180339022A1
公开(公告)日：2018-11-29
申请号：US16044561
申请日：2018-07-25
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , UNIVERSITÉ DE VERSAILLES SAINT-QUENTIN-EN-YVELINES , UNIVERSITÉ PARIS DIDEROT - PARIS 7
发明人： Alain COUVINEAU , Thierry VOISIN , Anne COUVELARD
IPC分类号： A61K38/22 , G01N33/566 , A61K31/713 , A61K39/395 , A61K45/06 , A61K49/00 , C07K16/28 , C12N15/115 , C12Q1/6886 , G01N33/574 , A61K45/00 , G01N33/74
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas. In particular, the present invention relates to an OX1R agonist for use in the treatment of hepatocellular carcinomain a subject in need thereof.
-
2.发明申请公开(公告)号：US20170202925A1
公开(公告)日：2017-07-20
申请号：US15320827
申请日：2015-06-23
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , ASSISTANCE PUBLIQUE -HÔPITAUX DE PARIS
CPC分类号： A61K38/22 , A61K45/06 , A61K2300/00
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
-
3.发明申请METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS 审中-公开用于治疗肝细胞癌的方法和药物组合物公开(公告)号：US20160339080A1
公开(公告)日：2016-11-24
申请号：US15112723
申请日：2015-01-22
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , UNIVERSITÉ DE VERSAILLES SAINT-QUENTIN-EN-YVELINES , UNIVERSITÉ PARIS DIDEROT - PARIS 7
发明人： Alain COUVINEAU , Thierry VOISIN , Anne COUVELARD
IPC分类号： A61K38/22 , C12N15/115 , A61K49/00 , G01N33/74 , A61K45/06 , A61K31/713 , C12Q1/68 , G01N33/574 , C07K16/28 , A61K39/395
CPC分类号： A61K38/22 , A61K31/713 , A61K39/39558 , A61K45/00 , A61K45/06 , A61K49/00 , C07K16/2869 , C07K2317/75 , C12N15/115 , C12N2310/16 , C12N2320/31 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/566 , G01N33/57438 , G01N33/74 , G01N2333/726 , G01N2500/00 , G01N2500/04
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas. In particular, the present invention relates to an OX1R agonist for use in the treatment of hepatocellular carcinomain a subject in need thereof.
摘要翻译： 本发明涉及用于治疗肝细胞癌的方法和药物组合物。 特别地，本发明涉及用于治疗有需要的受试者的肝细胞癌的OX1R激动剂。
-
4.发明申请公开(公告)号：US20180305458A1
公开(公告)日：2018-10-25
申请号：US15767843
申请日：2016-10-14
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , UNIVERSITÉ DE ROUEN NORMANDIE
CPC分类号： C07K16/2869 , A61K38/22 , A61P37/06 , A61P43/00 , C07K16/283 , Y02A50/385 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/423
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory disease. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R agonist.
-
公开(公告)号：US20180044393A1
公开(公告)日：2018-02-15
申请号：US15551334
申请日：2016-02-18
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER , UNIVERSITÉ DE MONTPELLIER
发明人： Alain COUVINEAU , Thierry VOISIN
IPC分类号： C07K14/575
CPC分类号： C07K14/575 , A61K38/00 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to Orexin-B polypeptides and uses thereof, in particular for the treatment of cancer. In particular, the polypeptide of the present invention comprises the amino acid sequence ranging from the amino acid residue at position 6 to the amino acid residue at position 28 in SEQ ID NO:2 wherein at least one amino acid residue position 6, 7, 8, 9, 10, 12, 13, 14, 19, 21 or 23 is substituted and the amino acid residues at position 11; 15; 16; 17; 18; 20; 22; 24; 25; 26; 27; and 28 are not deleted or substituted.
-
公开(公告)号：US20190151304A1
公开(公告)日：2019-05-23
申请号：US16300328
申请日：2017-05-09
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCJAE MÉDICALE , UNIVERSITÉ DE ROUEN NORMANDIE , UNIVERSITÉ PARIS DIDEROT - PARIS 7
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases. The inventors showed that orexin receptor antagonists have anti-inflammatory properties. Indeed, these compounds are antagonist for OX1R-mediated calcium mobilization but a full agonist for OX1R-mediated mitochondrial apoptosis, which is the mechanism involved in the improvement of resolution of inflammation observed in the models of colitis, multiple sclerosis and pancreatitis. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R antagonist.
-
公开(公告)号：US20180030135A1
公开(公告)日：2018-02-01
申请号：US15543739
申请日：2016-01-14
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHÉ MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER , UNIVERSITÉ DE MONTPELLIER
发明人： Alain COUVINEAU , Thierry VOISIN , Bruno ROBERT , Pascal NICOLE , Myriam CHENTOUF , Pierre MARTINEAU
IPC分类号： C07K16/28
CPC分类号： C07K16/286 , A61K39/00 , C07K2317/21 , C07K2317/33 , C07K2317/73 , C07K2317/75
摘要： The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
-
公开(公告)号：US20180296549A1
公开(公告)日：2018-10-18
申请号：US15525771
申请日：2015-11-10
发明人： Alain COUVINEAU , Valérie GRATIO , Pascal NICOLE , Thierry VOISIN
IPC分类号： A61K31/47 , A61K31/551 , A61K31/472 , A61K45/06 , A61P35/00
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.035 秒)
